US stocks lagging at midday as Brexit and US stimulus worries permeate markets

US stocks lagging at midday as Brexit and US stimulus worries permeate markets

Proactive Investors

Published

1.20pm: US stocks lagging at midsession US stocks were lower at midday as investors fretted about progress on agreeing a coronavirus (COVID-19) stimulus package and the seeming deterioration of talks between the UK and the EU on sealing a Brexit deal. The Dow Jones Industrial Average shed around 51 points at 29,950, while the S&P 500 index is off around 20 points at 3,647. The tech laden Nasdaq index lost over 95 points at 12,310. A US$908 billion pandemic relief package remains hanging in the balance in Washington as discussions continue. "The continued bickering between Republicans and Democrats over the proposed stimulus relief package is hanging over stocks," noted David Madden, market analyst at London-based CMC Markets. "In light of the disappointing jobless claims report yesterday, there are growing concerns the economic rebound is fading, so a firm fiscal response is needed," he added. On Brexit, the transition period ends on December 31 this year and both sides have said a 'no deal' on trade looks a likely outcome, which has made markets jumpy today. The pound fell 0.57% against the US dollar, while the FTSE 100 closed earlier 53 points down at 6,546. 10.00am: Proactive North America headlines: Gevo Inc (NASDAQ:GEVO) (FRA:ZGV3) hails United Airlines pledge to include sustainable aviation fuel in its bid to reduce greenhouse emissions BioSig Technologies Inc (NASDAQ:BSGM) announces the first commercial sale of its PURE EP Systems NexTech AR Solutions Corp (OTCQB:NEXCF) (CSE:NTAR) (FRA:N29) expands into China after naming convention and exhibition industry veteran Steven Seet as senior director of Asia Pacific Loop Insights Inc (CVE:MTRX) (OTCQB:RACMF) launches multilingual platform to support national programs; receives $4.6M from exercise of warrants Esports Entertainment Group Inc (NASDAQ:GMBL) (FRA:40Y1) says EGL to manage Arsenal’s esports team American Resources Corporation (NASDAQ:AREC) says subsidiary American Rare Earth obtains Pending Certified B Corporation status through B Lab 9.42am: Wall Street starts on back foot The main indices on Wall Street have started Friday’s session on the back foot as concerns over stimulus negotiations and rising cases of COVID-19 rattled market sentiment. In the first minutes of trading, the Dow Jones Industrial Average was down 0.39% at 29,882, while the S&P 500 fell 0.46% at 3,651 and the Nasdaq dropped 0.56% to 12,336. Amid the uncertainty of the political landscape, with a bleak outlook for Brexit negotiations also doing little to excite investors, traders seem content to take some profits following recent rallies. Even pharma firm Pfizer Inc (NYSE:PFE) fell 1.6% to US$41.20 despite news that its COVID-19 vaccine developed with BioNTech is likely to be approved for emergency use by the US Food and Drug Administration. 7.45am: Wall Street to head lower amid doubts over stimulus Doubts over the speed with which a financial stimulus programme could be introduced in the US are set to deter investors on Wall Street today. The Dow Jones Industrial Average is expected to open 200 points in the hole at a shade below 29,800 while the broader-based S&P 500 is seen shedding 32 points at 3,636. Even the Nasdaq Composite, which so often makes headway when the other two major indices retreat, is expected to shed 111 points at 12,295. “We're only just starting to see the impact of Thanksgiving in the US, where record cases and fatalities is an enormous problem going into the holiday period. Obviously, this isn't entirely the result of thanksgiving, it started before and not enough has been done to bring it under control, as we saw earlier in the year. The next couple of month will get ugly and the vaccines will do little to change that,” said Craig Erlam at OANDA Europe. “All the more reason why it's essential that Congress puts aside differences and finds agreement on a stimulus programme before the end of the year when past programmes expire. The bipartisan package put forward a couple of weeks ago may be the basis for what will be agreed and lawmakers are running out of time to make whatever concessions is necessary,” he added. On the subject of coronavirus cases, the US reported a worrying 224,000 new cases yesterday, was a record level for daily cases, albeit up a mere 3.1% week-on-week, which represents a slowing in the growth rate after Wednesday’s 10.6% increase and Tuesday’s 19.5% surge. “The seven-day average appears to be flattening, but this might just be due to last week's post-Thanksgiving catch-up in testing dropping out of the calculation. We'll have a much better idea of the underlying trend by early next week, but for now, it is fair to say that the spike after the holiday has been smaller than we feared,” said Ian Shepherdson, the chief economist at Pantheon Macroeconomics. “The rate of change of hospitalisations has nudged up slightly in recent days, thanks to the upturn in cases since Thanksgiving, but daily deaths are still reflecting the sharp rising trend in cases before the holiday. Deaths, therefore, likely will rise substantially further even if cases now run flat,” Shepherdson said. Four things to watch for on Friday: The macro calendar has a few snippets of data today including the US producer prices index (PPI), which provide insight on prices at the gates of American factories. Forecasts are estimating that the PPI will show a 0.2% rise in November compared to 0.3% in October Also in the diary is the Michigan consumer sentiment data for December, which is forecast to show a decline to 76 from 76.9 in November Share price reaction may also be eyed from media giant Walt Disney Co (NYSE:DIS) after the group unveiled a slate of upcoming new content for the coming years alongside a surge in customers signing up to its Disney+ streaming service Investors may also be eyeing Pfizer Inc (NYSE:PFE) following news that the FDA is planning to grant emergency use authorisation for its COVID-19 vaccine, developed in partnership with BioNTech

Full Article